Aug 20 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
EYLEA HD® (AFLIBERCEPT) INJECTION 8 MG APPLICATIONS FOR EXPANDED U.S. LABEL AND PREFILLED SYRINGE RECEIVE FDA REVIEW PERIOD EXTENSION
REGENERON PHARMACEUTICALS INC - FDA EXTENDS TARGET ACTION DATES FOR EYLEA HD TO Q4 2025
REGENERON PHARMACEUTICALS INC - FDA EXTENDED REVIEW DUE TO MAJOR AMENDMENT FROM THIRD-PARTY INSPECTION
REGENERON PHARMACEUTICALS INC: EYLEA HD REMAINS AVAILABLE IN U.S. THROUGH VIAL ADMINISTRATION